Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 December 2022 | Story André Damons | Photo Sonia Small
Dr Nicholas Pearce
Prof Nicholas Pearce has joined the Faculty of Health Sciences’ management team after being appointed Head of the School of Clinical Medicine. Prof Pearce is the former Head of the Department of Surgery at the UFS and led the Universitas Hospital’s COVID-19 Task Team.

During the height of the COVID-19 pandemic, Prof Nicholas Pearce led the COVID-19 Task Team of the Universitas Academic Hospital, ensuring that the hospital not only had enough Personal protective equipment (PPEs) and beds for patients, but also that the vaccination process ran smoothly. Now, the Best Doctor of the Year for 2022 – as named during this year’s National Annual Batho Pele Excellence Awards (NBPEA) – will lead the School of Clinical Medicine in the Faculty of Health Sciences at the University of the Free State (UFS).

Prof Pearce, former Head of the Department of Surgery at the UFS who served the faculty in multiple capacities over a long period, took up this position on 1 December 2022 – a position he is looking forward to.  

Create world-class doctors, maximise students’ full potential

“I’m excited about taking up my new position as Head of the School of Clinical Medicine. This is a role that comes with huge responsibility, and my vision is to create world-class doctors and to maximise each student’s full potential.  We, as university, are a national asset and need to grow and develop to be of service to the future of our country.  So, to lead a school with such a prestigious history is truly a privilege,” says Prof Pearce. 

According to him, the goal for the Medical School in the next five years should be determined by three main core drivers: service delivery, research, and teaching and training. He would like to be in a stronger position, with innovation that can produce world-class doctors (both undergraduate and postgraduate). 

If you look at the strategic plan of the UFS, says Prof Pearce, it is clear that, under the leadership of current Rector and Vice-Chancellor, Prof Francis Petersen, a period of regeneration and innovation is upon the university. Tied to this concept is the idea of self-evaluation and improvement. The idea of challenges and coming up with solutions excites him.  

“I think for a while, my main aim will be to bring the university, the provincial Department of Health, and the school in alignment, ensuring that we are all pulling in the same direction to achieve the same goal.”  

“At the end of the day, the goal here is to provide quality health care to the people of South Africa, while the Department of Health, the university, and society each function in different environments – coming together and understanding each other’s needs and having a common goal – excellent health care in this country for all our citizens.”

Lessons learned from surgery and running COVID-19 task teams

Prof Pearce, who was awarded the UFS Chancellor’s Medal for outstanding service during the April graduation ceremonies, says lessons learned from being both a surgeon and running COVID-19 task teams, are that strategic organisational processes need to be in place – systems strengthened, the policies and procedures adapted, and comprehensive planning taking place. 

However, he says, one must also bear in mind that we have a history of very high academic standards in the School of Clinical Medicine, so you want to improve on that rather than go backwards.

“I learned a lot from surgery and COVID-19 that will equip me in future. COVID-19 taught me about organisational management, disaster management, funding, resource management, people management skills, development, etc.  
“Running the Department of Surgery, one of the largest departments in the faculty with multiple inputs and personalities, has taught me that you are only as strong as the team behind you. I have an amazing team behind me in this new role, whether it is the dean, vice-dean, heads of department, administration, rectorate, and so forth.” 

He will continue to work at the Universitas Hospital; however, being fully employed by the university, he will only be doing some calls and working over weekends.  

“As a surgeon, theatre has always been my safe haven, my place of meditation, my place of peace, and I am sad to say goodbye to surgery and the Department of Surgery – it has been loyal, and I am grateful to everyone in the department; but I think as with all good things, there is a time to come and a time to go.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept